Skip to main content

Month: November 2020

FDA Approves Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of Neuroblastoma

NEW YORK, Nov. 25, 2020 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the U.S. Food and Drug Administration (“FDA”) has approved DANYELZA (naxitamab-gqgk) 40mg/10ml. DANYELZA is indicated, in combination with granulocyte-macrophage colony-stimulating factor (“GM-CSF”), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. This indication is approved under accelerated approval regulation based on overall...

Continue reading

Rogers Sugar Inc.: 4th Quarter 2020 Results

ADJUSTED EBITA OF $92.3 MILLION FOR FISCAL 2020 – 5% INCREASE OVER PRIOR YEAR SUGAR REVENUES HIGHER DUE TO RECORD BREAKING SALES VOLUMES IN THE FOURTH QUARTER ACROSS ALL MARKET SEGMENTS STRONG SALES VOLUME IN MAPLE DRIVING HIGHER REVENUE FOR THE QUARTER AND THE YEARMONTREAL, Nov. 25, 2020 (GLOBE NEWSWIRE) — Rogers Sugar Inc.’s (the “Company” or “Rogers”) (TSX: RSI) today reported fourth quarter and year-to-date fiscal 2020 results. The Company recorded adjusted EBITDA (1) of $31.2 million and $92.3 million for fourth quarter and fiscal 2020, respectively, versus $22.2 million and $87.8 million for the comparable periods last year.“Our strong fiscal 2020 performance is a direct result of the efforts of our agile committed team and our long-term strategic vision to continue to build a resilient, successful company,” said John...

Continue reading

Rogers Sugar Inc. : Résultats du quatrième trimestre de l’exercice 2020

BAIIA AJUSTÉ DE 92,3 MILLIONS DE DOLLARS POUR L’EXERCICE 2020 : HAUSSE DE 5 % PAR RAPPORT À L’EXERCICE PRÉCÉDENT HAUSSE DES PRODUITS DU SECTEUR DU SUCRE RÉSULTANT DES VOLUMES DE VENTES RECORD AU QUATRIÈME TRIMESTRE DANS TOUS LES SEGMENTS DE MARCHÉ FORT VOLUME DE VENTES DU SECTEUR DES PRODUITS DE L’ÉRABLE GÉNÉRANT DES PRODUITS PLUS ÉLEVÉS POUR LE TRIMESTRE ET L’EXERCICEMONTRÉAL, 25 nov. 2020 (GLOBE NEWSWIRE) — Rogers Sugar Inc. (la « Société » ou « Rogers ») (TSX : RSI) annonce aujourd’hui ses résultats du quatrième trimestre et de l’exercice 2020. La Société a inscrit un BAIIA ajusté1) de 31,2 millions de dollars pour le quatrième trimestre et de 92,3 millions de dollars pour l’exercice 2020, comparativement à 22,2 millions de dollars et à 87,8 millions de dollars pour la période correspondante de l’exercice précédent et l’exercice...

Continue reading

FirstMark Horizon Acquisition Corp. Announces the Separate Trading of its Class A Common Stock and Redeemable Warrants Commencing November 27, 2020

NEW YORK, NY, Nov. 25, 2020 (GLOBE NEWSWIRE) — FirstMark Horizon Acquisition Corp. (NYSE: FMAC.U) (the “Company”) today announced that, commencing November 27, 2020, holders of the units sold in the Company’s initial public offering of 41,400,000 units completed on October 8, 2020, may elect to separately trade the shares of Class A common stock and redeemable warrants included in the units. Those units not separated will continue to trade on the New York Stock Exchange (“NYSE”) under the symbol “FMAC.U,” and the shares of Class A common stock and redeemable warrants that are separated will trade on NYSE under the symbols “FMAC” and “FMAC WS,” respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Holders of units will need to have their brokers contact Continental Stock...

Continue reading

Shattuck Labs to Present Virtually at Evercore ISI 3rd Annual HealthCONx Conference

AUSTIN, TX and DURHAM, NC, Nov. 25, 2020 (GLOBE NEWSWIRE) — Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in the Evercore ISI 3rd Annual HealthCONx conference being held December 1-3, 2020.Conference Presentation DetailsConference: Evercore ISI 3rd Annual HealthCONxFormat: Fireside chat with Umer RaffatPresenters: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer and Andrew Neill, Shattuck’s Vice President of Finance and Corporate StrategyDate: December 2, 2020Time: 1:00 p.m. ESTWebcast Link: Available HereThe live webcast of the fireside chat will be available on the Events &...

Continue reading

Mallard Acquisition Corp. Announces the Separate Trading of its Common Stock and Warrants, Commencing November 27, 2020

New York, NY, Nov. 25, 2020 (GLOBE NEWSWIRE) — Mallard Acquisition Corp. (NASDAQ: MACUU) (the “Company”) announced that, commencing November 27, 2020, holders of the units sold in the Company’s initial public offering may elect to separately trade shares of the Company’s common stock and warrants included in the units. Common stock and warrants that are separated will trade on the Nasdaq Capital Market under the symbols “MACU” and “MACUW,” respectively. Those units not separated will continue to trade on the Nasdaq Capital Market under the symbol “MACUU.”This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities of the Company, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration...

Continue reading

Celestica to Hold a Virtual Meeting About Its Joint Design and Manufacturing Business With Analysts and Investors

TORONTO, Nov. 25, 2020 (GLOBE NEWSWIRE) — Celestica Inc. (NYSE: CLS)(TSX: CLS), a leader in design, manufacturing and supply chain solutions for the world’s most innovative companies, today announced it will hold an analyst and investor meeting on December 2 at 4:00pm ET. During the meeting, Celestica’s management will provide an overview of Celestica’s Joint Design and Manufacturing business, and will reaffirm Q4 2020 guidance and outline near-term expectations.To participate in the conference call in listen-only mode, please dial (647) 788-4919 or 1 (877) 291-4570. To ensure your participation, please call in approximately ten minutes prior to the scheduled start of the call. Analysts will have the opportunity for a Q&A with speakers following the formal remarks.A webcast is also available at:https://onlinexperiences.com/Launch/QReg/ShowUUID=D17311B8-8E5F-460E-A143-D9B5E264D255 A...

Continue reading

Healthcare Realty Trust Announces Release of its Second Annual Corporate Responsibility Report

NASHVILLE, Tenn., Nov. 25, 2020 (GLOBE NEWSWIRE) — Healthcare Realty Trust Incorporated (NYSE:HR) today announced the release of its second annual Corporate Responsibility Report covering Environmental, Social, and Governance (ESG) initiatives and accomplishments. The report includes the Company’s initial Key Performance Indicator (KPI) targets that are aligned with the U.N. Sustainable Development Goals.The Company also announced that it has expanded Carla Baca’s responsibilities to include leading the Company’s Corporate Responsibility initiatives. Ms. Baca joined the Company in 2011 and currently oversees investor relations. Healthcare Realty’s sustainability reports, principles and policies are available on the Company’s website: https://www.healthcarerealty.com/sustainability/Healthcare Realty Trust is a real estate investment...

Continue reading

Nemaska Lithium Completes Share Exchange with Residual Nemaska Lithium

MONTRÉAL, Nov. 25, 2020 (GLOBE NEWSWIRE) — Nemaska ​​Lithium Inc. (“Nemaska Lithium” or the “Corporation”) announces today that it has completed the previously announced exchange of its common shares, on a one-for-one basis, for common shares of NMX Residual Liabilities Inc. (“Residual Nemaska Lithium”), resulting in Residual Nemaska Lithium having become a successor reporting issuer under applicable Canadian securities laws (the “Exchange”). All issued and outstanding options, warrants and other securities of the Corporation (including securities convertible, exchangeable or exercisable for shares of the Corporation) have also been cancelled for no consideration. The Exchange was effected and completed in accordance with and pursuant to the approval and vesting order of the Superior Court of Québec (Commercial Division) issued...

Continue reading

Nemaska Lithium réalise l’échange d’actions avec l’entité restante de Nemaska Lithium

MONTRÉAL, 25 nov. 2020 (GLOBE NEWSWIRE) — Nemaska Lithium Inc. (« Nemaska Lithium » ou la « Société ») annonce aujourd’hui qu’elle a réalisé l’échange annoncé précédemment de ses actions ordinaires, au pair, contre des actions ordinaires d’Obligations résiduelles NMX Inc. (l’« entité restante de Nemaska Lithium »), aux termes duquel l’entité restante de Nemaska Lithium est devenue un émetteur assujetti remplaçant en vertu des lois sur les valeurs mobilières canadiennes applicables (l’ « échange »). Tous les bons de souscription, options et autres titres de la Société émis et en circulation (y compris les titres permettant d’obtenir des actions de la Société par conversion, échange ou exercice) ont également été annulés sans contrepartie. L’échange a été effectué et réalisé conformément à l’ordonnance d’approbation et de dévolution...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.